Skip to main content

Advertisement

Table 5 Investigator assessment of best clinical response a

From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Best clinical response All patients
(N = 46), n (%)
CRb 2 (4)
PR 2 (4)
SD 13 (28)
PD 26 (57)
Unknownc 3 (7)
  1. aPer response criteria in Cheson et al. [11].
  2. bBoth CRs were confirmed.
  3. cNo post-baseline evaluations available.